Blood and Marrow Transplant and Cellular Immunotherapy![]() |
Find a Doctor![]() Claudio Anasetti, MD
Sub Specialty: Medical Oncology Program: Blood and Marrow Transplant and Cellular Immunotherapy
Overview
Cancer Focus: Leukemia, Multiple Myeloma-Plasma Cell Tumor, Myelodysplastic Syndromes (MDS) Dr. Claudio Anasetti is Emeritus Member of the Department of Blood & Marrow Transplantation and Cellular Immunotherapy at the Moffitt Cancer Center and Research Institute in Tampa, Florida, U.S.A. In 1980, Dr. Anasetti graduated as M.D. cum laude from the University of Perugia School of Medicine. He trained in Internal Medicine at the University of Perugia, in Italy. He pursued training as Fellow in Immunology at the Children’s Memorial Hospital, with Dr. Robert A. Good in Oklahoma City, Oklahoma, and Fellow in Oncology, at the University of Washington and the Fred Hutchinson Cancer Research Center with Dr. E. Donnall Thomas (Nobel Prize recipient), in Seattle, Washington. Dr. Anasetti established his research immunology laboratory with Drs. John A. Hansen and Paul J. Martin at the Fred Hutchinson Cancer Research Center, became the leader of the first and largest unrelated donor marrow transplant program in the world and developed his academic career to the rank of Full Member at the Fred Hutchinson and Full Professor at University of Washington, in Seattle, Washington. Dr. Anasetti’s lab was the first to identify the CD28 pathway as key for establishing immunological tolerance in humans. Also, Dr. Anasetti established guiding principles for the selection of partially matched related and unrelated donors that have stood for the last 35 years. In 2004, Dr. Anasetti moved from Seattle to Tampa in Florida, where he expanded a small transplant program to develop into one of the top 5 programs by size and reputation in the U.S.A. In 2015 at the Moffitt Cancer Center, Dr. Anasetti launched the Immune Cell Therapy Program that was instrumental for the clinical development and later F.D.A. approval of the first CD19-specific, chimeric antigen receptor T cell for the treatment of relapsed or refractory lymphoma. Dr. Anasetti serves currently on the data and safety monitoring boards of Kite and Allogene, companies that are developing CAR T cells for cancer immunotherapy. To date, Dr. Anasetti has co-authored over 500 peer-reviewed publications and book chapters. A past president of the American Society of Blood and Marrow Transplantation, Dr. Anasetti has been a charter member of the National Institutes of Health Clinical Oncology Study Section, and chair of the Strategic Capacity Initiative Physician Workforce Group for the National Marrow Donor Program. In addition, Dr. Anasetti is on several national editor boards and a journal reviewer for numerous professional journals, including the New England Journal of Medicine. Education & TrainingBoard Certification:
Fellowship:
Residency:
Medical School:
Participating Trials
If you believe you are eligible for one of these trials or studies, please call
Publications
Patient Comments
Overall Satisfaction
0
0 patients rated this provider
The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. These surveys assess the experience of our patients when visiting us for an Outpatient Clinic, Urgent Care or Virtual Health (Telemedicine) visit. Responses are measured on a scale of 1 to 5 with 5 being the best score.
Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question. Comments ()Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy. We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic. Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months. Learn more about our patient commentsProvider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:
|